Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Isotretinoin for Proliferative Vitreoretinopathy
NCT01445028Phase 4Completed
- Sponsor
- Wills Eye Hospital
- Start
- Sep 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of isotretinoin in Proliferative Vitreoretinopathy (PVR) and retinal detachment (2 arms), sponsored by Wills Eye Hospital. Primary endpoint: Rate of Retinal Attachment at 3 months. Started Sep 2011; status: completed.
02
Drugs
isotretinoin
03
Conditions
Proliferative Vitreoretinopathy (PVR)retinal detachment
Beyond the preview
Go deeper on NCT01445028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01445028.